Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
28/09/2026 08:04
BRIEF-Chugai Pharmaceutical Co Ltd - Regarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA Sept 28 (Reuters) - Chugai Pharmaceutical Co Ltd 4519.T:
CHUGAI PHARMACEUTICAL CO LTD - REGARDING DISCONTINUATION OF DEVELOPMENT OF GYM329 (EMUGROBART) FOR OBESITY, RETURN OF LICENSE AND RESUMPTION OF DEVELOPMENT FOR SMA
Source text: ID:nTSub8408e
Further company coverage: 4519.T
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey